EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Depletion of Tregs from CD4 + CAR ‐T cells enhances the tumoricidal effect of CD8 + CAR ‐T cells in anti‐ CD19 CAR ‐T therapy

Yunyan Sun, Jinyan Liu, Dong Zhan, Jia Wei, Li XianShi, Rui Zhang, Ci Duan, Disi Zhang, Xiaorong Tang, Tuo Lin, Limei Li, Xun Lai iD

The FEBS Journal · 2025

DOI: 10.1111/febs.17326 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, 2025. Verfasst von Yunyan Sun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunn…. Hauptthemen laut MEDLINE: Antigens, CD19, T-Lymphocytes, Regulatory, CD8-Positive T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Qiu Lu Gui Expert Workstation in Yunnan Province, The Joint Project of Kunming Medical University and Science and Technology Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T (CAR‐T) cell therapy, which targets CD19 for hematological malignancies, represents a breakthrough in cancer immunotherapy. However, some patients may develop resistance to CAR‐T treatment, underscoring the importance of optimizing CAR‐T design to enhance responsiveness. Here, we investigated the impact of different subpopulations in anti‐CD19 CAR‐T cells on the tumoricidal effect. Different populations of anti‐CD19 CAR‐T cells were isolated by magnetic‐activated cell sorting (MACS). Their lytic activities on the acute lymphocytic leukemia cell line SUP‐B15 and diffuse large B‐cell lymphoma EB‐3 cell line were examined in a co‐culture system. The anti‐tumorigenic outcome of different CAR‐T cell compositions was evaluated in a xenograft mouse model of EB‐3 cells. CD8 + CAR‐T cells exhibited the most potent tumoricidal activity against SUP‐B15 and EB‐3 cells. Additionally, CD4 + T helper cells enhanced the lytic effects of CD8 + CAR‐T cells by increasing the availability of interleukin‐2 (IL‐2). Depleting CD25 + Treg (T regulatory) cells from CD4 + CAR‐T population further augmented the tumoricidal activity of CD8 + CAR‐T cells by preventing IL‐2 deprivation. Consistently, in vivo experiments demonstrated that the CD4 + CD25 + Treg population dampened the antitumor activity of CD8 + CAR‐T cells, while depletion of Tregs from CD4 + CAR‐T cells enhanced the tumoricidal effect. These findings emphasize the potential role of CAR Treg cells in therapeutic resistance, suggesting that the depletion of Tregs in the anti‐CD19 CAR‐T population may serve as a strategy to augment the anticancer effect of CD8 + CAR‐T cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD19T-Lymphocytes, RegulatoryCD8-Positive T-LymphocytesImmunotherapy, AdoptiveReceptors, Chimeric AntigenCD4-Positive T-LymphocytesLymphoma, Large B-Cell, DiffuseAnimalsHumansMiceCell Line, TumorXenograft Model Antitumor AssaysInterleukin-2Interleukin-2 Receptor alpha Subunit

Stichwörter der Autor:innen

CAR‐TCD19Tregscytotoxictumoricial

Substanzen

Antigens, CD19Receptors, Chimeric AntigenInterleukin-2Interleukin-2 Receptor alpha SubunitCD19 molecule, human

Autor:innen und Institutionen

  • Department of Hematology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China.
  • Department of Human Anatomy and Histology & Embrology, School of Basic Medical Sciences, Kunming Medical University, China.
  • Yunnan College of Business Management, Kunming, China.

ORCID-Profile: Xun Lai

Förderung

  • National Natural Science Foundation of China
  • Qiu Lu Gui Expert Workstation in Yunnan Province
  • The Joint Project of Kunming Medical University and Science and Technology Agency
  • Kunming Joint Special Project
  • Yunnan Fundamental Research Projects

Zitieren

APA

Sun, Y., Liu, J., Zhan, D., Wei, J., XianShi, L., Zhang, R., Duan, C., Zhang, D., Tang, X., Lin, T., Li, L., & Lai, X. (2025). Depletion of Tregs from CD4 + CAR ‐T cells enhances the tumoricidal effect of CD8 + CAR ‐T cells in anti‐ CD19 CAR ‐T therapy. The FEBS Journal. https://doi.org/10.1111/febs.17326

Vancouver

Sun Y, Liu J, Zhan D, Wei J, XianShi L, Zhang R, et al. Depletion of Tregs from CD4 + CAR ‐T cells enhances the tumoricidal effect of CD8 + CAR ‐T cells in anti‐ CD19 CAR ‐T therapy. The FEBS Journal. 2025. doi:10.1111/febs.17326

BibTeX
@article{Sun2025,
  author = {Sun, Yunyan and Liu, Jinyan and Zhan, Dong and Wei, Jia and XianShi, Li and Zhang, Rui and Duan, Ci and Zhang, Disi and Tang, Xiaorong and Lin, Tuo and Li, Limei and Lai, Xun},
  title = {Depletion of Tregs from CD4 + CAR ‐T cells enhances the tumoricidal effect of CD8 + CAR ‐T cells in anti‐ CD19 CAR ‐T therapy},
  journal = {The FEBS Journal},
  year = {2025},
  doi = {10.1111/febs.17326}
}
Kostenlos starten →